SCHEMBL422985

SCHEMBL422985

C#CCN1COCN=C1N[N+](=O)[O-]

nearest known ligand 0.34

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL419778 0.78 POLB (0.34) POLBSMN1; SMN2
SCHEMBL424803 0.75 POLB (0.33) POLBSMN1; SMN2
SCHEMBL422028 0.73 POLB (0.32) POLBSMN1; SMN2
SCHEMBL421951 0.71 PKM (0.39) POLBSMN1; SMN2
SCHEMBL422862 0.70 POLB (0.30) POLBSMN1; SMN2
SCHEMBL8700244 0.70 POLB (0.30) POLBSMN1; SMN2
Desmethylthiamethoxam SCHEMBL8706857 0.70 MAPT (0.36) POLBSMN1; SMN2
SCHEMBL8702344 0.68 CHRNB2 (0.52) SMN1; SMN2
SCHEMBL421338 0.61
SCHEMBL24356067 0.51 LMNA (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022053-A1 Oxadiazine Derivatives SYNGENTA CROP PROTECTION, INC. (US) 2012-01-26 US disclosed
US-7655650-B2 Oxadiazine derivatives Syngenta Corporation (US) 2010-02-02 US disclosed
US-20070219188-A1 Oxadiazine Derivatives SYNGENTA CROP PROTECTION, INC. (US) 2007-09-20 US disclosed
US-20030232821-A1 Oxadiazine derivatives MAIENFISCH PETER (CH) 2003-12-18 US disclosed
EP-0580553-B1 Oxadiazine derivatives SYNGENTA PARTICIPATIONS AG (CH) 2003-11-26 EP disclosed
US-6376487-B1 SELECTIVE INSECTICIDES FOR KILLING FLIES, ROACHES, WEEVILS, AND OTHER PESTS; FOR USE ON COTTON, LEGUMES, FRUITS, CEREALS, BEANS, AND OTHER CROPS SYNGENTA INVESTMENT CORP. 2002-04-23 US disclosed
US-6022871-A INSECTICIDES NOVARTIS CORPORATION (US) 2000-02-08 US disclosed
US-5852012-A Oxadiazine derivatives NOVARTIS CORPORATION (US) 1998-12-22 US disclosed
EP-0580553-A2 Oxadiazine derivatives CIBA-GEIGY AG (CH) 1994-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219188-A1 Oxadiazine Derivatives CBR3, AOC3, AOC2 POLB 2769/4885SMN1; SMN2 4391/4885
US-20030232821-A1 Oxadiazine derivatives HCN1, SCO2, AOC3 POLB 2849/4885SMN1; SMN2 2843/4885
US-20120022053-A1 Oxadiazine Derivatives CBR3, AOC3, AOC2 POLB 2769/4885SMN1; SMN2 4391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.